| Summary of Significant Research and Development and General and Administrative Expense to CODM |
The table below summarizes the significant research and development and general and administrative expense categories regularly provided to the CODM for the three months ended March 31, 2025 and March 31, 2024:
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, |
|
(in thousands) |
|
2025 |
|
|
2024 |
|
Revenue |
|
$ |
29 |
|
|
$ |
17,584 |
|
Operating expenses |
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
Direct research and development expenses by product candidate: |
|
|
|
|
|
|
PBGENE-HBV external development costs |
|
|
1,601 |
|
|
|
3,056 |
|
PBGENE-DMD external development costs |
|
|
2,438 |
|
|
|
175 |
|
PBGENE-3243 external development costs |
|
|
2,165 |
|
|
|
1,212 |
|
Platform development and early-stage research expenses: |
|
|
|
|
|
|
Employee-related costs (including share-based compensation) |
|
|
5,300 |
|
|
|
5,380 |
|
Laboratory supplies and services |
|
|
454 |
|
|
|
744 |
|
CMOs and outsourced research and development |
|
|
56 |
|
|
|
228 |
|
Facility-related costs, laboratory equipment, and maintenance |
|
|
728 |
|
|
|
810 |
|
Depreciation and amortization |
|
|
340 |
|
|
|
891 |
|
Licensing fees and other research and development costs |
|
|
506 |
|
|
|
847 |
|
Total research and development expenses |
|
$ |
13,588 |
|
|
$ |
13,343 |
|
General and administrative expense |
|
|
|
|
|
|
Employee-related costs (including share-based compensation) |
|
|
5,460 |
|
|
|
5,009 |
|
Consulting and professional services |
|
|
1,536 |
|
|
|
1,467 |
|
Other operating expenses and all other costs |
|
|
1,557 |
|
|
|
1,952 |
|
Total general and administrative expenses |
|
$ |
8,553 |
|
|
$ |
8,428 |
|
Total operating expenses |
|
$ |
22,141 |
|
|
$ |
21,771 |
|
Operating loss |
|
|
(22,112 |
) |
|
|
(4,187 |
) |
Total other income |
|
|
1,547 |
|
|
|
12,775 |
|
(Loss) income from operations |
|
$ |
(20,565 |
) |
|
$ |
8,588 |
|
Net (loss) income |
|
$ |
(20,565 |
) |
|
$ |
8,588 |
|
|